0001104659-23-114809.txt : 20231106 0001104659-23-114809.hdr.sgml : 20231106 20231106170021 ACCESSION NUMBER: 0001104659-23-114809 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231103 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20231106 DATE AS OF CHANGE: 20231106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NeuBase Therapeutics, Inc. CENTRAL INDEX KEY: 0001173281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465622433 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35963 FILM NUMBER: 231380643 BUSINESS ADDRESS: STREET 1: 350 TECHNOLOGY DRIVE CITY: PITTSBURGH STATE: PA ZIP: 15219 BUSINESS PHONE: 412-763-3350 MAIL ADDRESS: STREET 1: 350 TECHNOLOGY DRIVE CITY: PITTSBURGH STATE: PA ZIP: 15219 FORMER COMPANY: FORMER CONFORMED NAME: Ohr Pharmaceutical Inc DATE OF NAME CHANGE: 20090819 FORMER COMPANY: FORMER CONFORMED NAME: BBM HOLDINGS, INC. DATE OF NAME CHANGE: 20070402 FORMER COMPANY: FORMER CONFORMED NAME: PRIME RESOURCE INC DATE OF NAME CHANGE: 20020513 8-K 1 tm2330001d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 3, 2023

NeuBase Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-35963		46-5622433
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

350 Technology Drive, Pittsburgh, PA		15219
(Address of Principal Executive Offices)		(Zip Code)

	(412) 763-3350
	(Registrant’s Telephone Number, Including Area Code)

	N/A
	(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	NBSE	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 3, 2023, NeuBase Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, because the closing bid price for its common stock has been below $1.00 per share for 30 consecutive business days, it no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days.

The Notice has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until May 1, 2024 to regain compliance with the Minimum Bid Price Requirement. During the compliance period, the Company’s shares of common stock will continue to be listed and traded on The Nasdaq Capital Market. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during the 180 calendar day grace period.

In the event the Company is not in compliance with the Minimum Bid Price Requirement by May 1, 2024, the Company may be afforded a second 180 calendar day grace period. To qualify, the Company would be required to meet the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement. In addition, the Company would be required to provide written notice of its intention to cure the minimum bid price deficiency during this second 180-day compliance period by effecting a reverse stock split, if necessary.

The Company intends to actively monitor the bid price for its common stock between now and May 1, 2024 and will consider available options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or that the Company will otherwise be in compliance with the other listing standards for The Nasdaq Capital Market.

Forward-Looking Statements

Except for the factual statements made herein, information contained in this Current Report on Form 8-K consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects or future events, as well as words such as “believes,” “intends,” “expects,” “plans” and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that the Company will meet the Minimum Bid Price Requirement during any compliance period or otherwise in the future, otherwise meet Nasdaq compliance standards, or that Nasdaq will grant the Company any relief from delisting as necessary or whether the Company can agree to or ultimately meet applicable Nasdaq requirements for any such relief. Reference is also made to other factors detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. The forward-looking statements contained in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K and the Company assumes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this Current Report on Form 8-K, unless required by law.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEUBASE THERAPEUTICS, INC.
	(Registrant)


Date: November 6, 2023	By:	/s/ Todd P. Branning
		Todd P. Branning
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-101.SCH 2 nbse-20231103.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 nbse-20231103_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 nbse-20231103_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 03, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 03, 2023
Entity File Number	001-35963
Entity Registrant Name	NeuBase Therapeutics, Inc.
Entity Central Index Key	0001173281
Entity Tax Identification Number	46-5622433
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	350 Technology Drive
Entity Address, City or Town	Pittsburgh
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	15219
City Area Code	412
Local Phone Number	763-3350
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NBSE
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 6 tm2330001d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001173281 2023-11-03 2023-11-03 iso4217:USD shares iso4217:USD shares false 0001173281 8-K 2023-11-03 NeuBase Therapeutics, Inc. DE 001-35963 46-5622433 350 Technology Drive Pittsburgh PA 15219 412 763-3350 false false false false Common Stock, par value $0.0001 per share NBSE NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " 5T0 !X;"]W;W)K8F]O:RYX M;6Q02P$"% ,4 " )B&97)!Z;HJT #X 0 &@ @ &] M$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " )B&97 M99!YDAD! #/ P $P @ &B$@ 6T-O;G1E;G1?5'EP97-= :+GAM;%!+!08 "0 ) #X" #L$P ! end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://neubasetherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nbse-20231103.xsd nbse-20231103_lab.xml nbse-20231103_pre.xml tm2330001d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2330001d1_8k.htm": { "nsprefix": "NBSE", "nsuri": "http://neubasetherapeutics.com/20231103", "dts": { "schema": { "local": [ "nbse-20231103.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "nbse-20231103_lab.xml" ] }, "presentationLink": { "local": [ "nbse-20231103_pre.xml" ] }, "inline": { "local": [ "tm2330001d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://neubasetherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330001d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330001d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001104659-23-114809-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-114809-xbrl.zip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end